0000950170-24-030479.txt : 20240312
0000950170-24-030479.hdr.sgml : 20240312
20240312215620
ACCESSION NUMBER: 0000950170-24-030479
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brumm Joshua T
CENTRAL INDEX KEY: 0001528826
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 24744469
MAIL ADDRESS:
STREET 1: ZELTIQ AESTHETICS INC.
STREET 2: 4698 WILLOW ROAD SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
4
X0508
4
2024-03-08
0001818794
Dyne Therapeutics, Inc.
DYN
0001528826
Brumm Joshua T
1560 TRAPELO ROAD
WALTHAM
MA
02451
true
true
false
false
CEO & President
true
Common Stock
2024-03-08
4
M
false
153931
5.54
A
708316
D
Common Stock
2024-03-08
4
M
false
209412
5.54
A
917728
D
Common Stock
2024-03-08
4
S
false
202238
25.30
D
715490
D
Common Stock
2024-03-08
4
S
false
160670
26.72
D
554820
D
Common Stock
2024-03-08
4
S
false
435
27.38
D
554385
D
Common Stock
2024-03-11
4
M
false
50000
5.54
A
604385
D
Common Stock
2024-03-11
4
S
false
40072
25.42
D
564313
D
Common Stock
2024-03-11
4
S
false
9928
26.10
D
554385
D
Common Stock
2024-03-11
4
S
false
7769
26.12
D
546616
D
Common Stock
2024-03-11
4
S
false
8618
25.93
D
537998
D
Stock option (right to buy)
5.54
2024-03-08
4
M
false
153931
0
D
2030-07-30
Common Stock
153931
0
D
Stock option (right to buy)
5.54
2024-03-08
4
M
false
209412
0
D
2030-07-30
Common Stock
209412
133269
D
Stock option (right to buy)
5.54
2024-03-11
4
M
false
50000
0
D
2030-07-30
Common Stock
50000
83269
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive.
Includes 513,913 unvested RSUs.
The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020.
/s/ Richard Scalzo, Attorney-in-Fact
2024-03-12